塔尔苏斯制药公司第四季度GAAP每股收益$(0.60)优于预期$(0.75)，销售额$66.41M超预期$58.33M

财报速递2025-02-25
塔尔苏斯制药公司（纳斯达克股票代码：TARS）报告每股亏损$(0.60)，优于分析师预期的每股亏损$(0.75)，超出预期20%。与去年同期每股亏损$(1.31)相比，提高了54.2%。公司报告的季度销售额为$66.41百万，超出了分析师预期的$58.33百万，增长了13.85%。与去年同期销售额为$13.08百万相比，增长了407.86%。

以上内容来自Benzinga Earnings专栏，原文如下：

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.75) by 20 percent. This is a 54.2 percent increase over losses of $(1.31) per share from the same period last year. The company reported quarterly sales of $66.41 million which beat the analyst consensus estimate of $58.33 million by 13.85 percent. This is a 407.86 percent increase over sales of $13.08 million the same period last year.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法